Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
National Breast Cancer Study of Epirubicin + CMF v Classical CMF Adjuvant Therapy
NCT00003577Phase 3Completed
- Sponsor
- University Hospitals Birmingham
- Start
- Mar 1996
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 3, randomised trial of epirubicin in breast cancer (2 arms), sponsored by University Hospitals Birmingham. Primary endpoints: Disease-Free Survival at 10 years and Overall Survival at 10 years. Started Mar 1996; status: completed.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00003577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00003577.